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ABSTRACT 
Objectives: Induction of labour is a part of an active prenatal care nowadays and the ideal method of that procedure still 
remains to be identified. The purpose of this study was to evaluate effectiveness of misoprostol vaginal insert as compared 
to dinoprostone gel for delivery induction in pregnant women without any comorbidities. 
Material and methods: It was a retrospective cohort study of 240 pregnant women. The primary study outcome was 
successful delivery. Other analysed parameters included time to delivery of a baby, time to the beginning of the first stage 
of labour, time to vaginal delivery, and duration of all delivery stages. We compared both methods regarding maternal 
complications during and after delivery. We also reviewed neonatal outcomes such as birth weight, birth length and 
1-minute Apgar scores. 
Results: The patients’ basic characteristics were similar regarding their age, gravidity, parity, height, weight and Bishop 
score. Time to any delivery and to the onset of a labour in the misoprostol group versus in the dinoprostone group was 
14.5 vs 35.6 h (p < 0.001) and 9.9 h vs 25.3 h (p < 0.001) respectively. The chance of the beginning of labour and the baby’s 
delivery over time has been observed to be approximately two times higher for misoprostol as compared to dinoprostone. 
Conclusions: Our study showed that using misoprostol vaginal insert in comparison to dinoprostone seems to shorten the 
time to beginning of the first stage of labour as well as the time to the delivery itself. Some lower Apgar scores observed 
in the misoprostol group requires further investigation.
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INTRODUCTION
Finding a safe, quick and effective method of labour in-
duction is a crucial part of a growing need for active prenatal 
care. Decision on the right moment to complete a preg-
nancy that would be the best for both the baby and the 
mother has been always a debatable issue. Modern medi-
cine has developed only a few tools to manage an unfavour-
able cervix which may be shortly divided into mechanical 
and pharmacological methods of preinduction. In the final 
step, induction of delivery involves oxytocin administra-
tion which strengthens the uterine contractions leading to 
childbirth. In current practice, no cervical ripening method 
appears superior to the others considering their overall ef-
fectiveness and safety outcomes [1], which indicates that 
the ideal method of labour preinduction remains to be 
identified. Prostaglandins are commonly used in obstet-
rics nowadays. Dinoprostone is a natural E2 prostaglandin 
produced by decidua and amnion, it causes relaxation of 
cervical collagen and develops uterine fibres contractions 
[2]. Misoprostol is a synthetic analogue of E1 prostaglandin 
and, although it was originally registered as a drug in the 
prevention and treatment of stomach ulcer disease [3], 
nowadays it is widely used in obstetrics also in preinduc-
tion of labour [4]. 
Objectives 
The purpose of this study was to evaluate effectiveness 
and safety of misoprostol vaginal insert at a dose of 0.2 mg 
(Misodel, Ferring Pharmaceuticals Poland sp. z o.o) as com-
pared to dinoprostone gel at a dose of 0.5 mg (Prepidil, Pfizer 
Polska Sp. z o.o.), administered in daily clinical practice for 
delivery induction in pregnant women without any comor-
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bidities. Additionally, we evaluated whether mothers’ age 
affected clinical outcomes.
MATERIAL AND METHODS 
It was a retrospective cohort study that included preg-
nant women requiring labour induction for either medical 
or obstetric indications, hospitalized at the Obstetric and 
Perinatology Department at the University Hospital in Cra-
cow between January 2015 and April 2019.
Inclusion criteria were (1) singleton gestation, (2) cephalic 
foetus presentation, (3) full-term pregnancy, (4) Bishop’s 
score ≤ 4, (5) reactive foetal heart rate (FHR) pattern, and (6) 
lack of spontaneous uterine contractions before administra-
tion of the drug.
Patients were excluded for the following reasons: 
(1) malpresentation, (3) estimated foetal weight > 4500 g 
(4) placenta previa or unexplained vaginal bleeding, (5) vasa 
previa, (6) other known contraindications to vaginal delivery, 
(7) any contraindication to receiving prostaglandins, (8) pre-
vious caesarean delivery or uterine surgery, (9) preterm de-
livery. Other exclusion criteria included maternal comorbidi-
ties such as: hypertension, diabetes mellitus, intrahepatic 
cholestasis of pregnancy, asthma, and thrombocytopenia. 
The primary study outcome was successful vaginal de-
livery. Other analysed parameters included time from drug 
administration to vaginal delivery, to any (vaginal or by 
Caesarean section) delivery, and time to the onset of labour 
defined as regular uterine contradictions at least every ten 
minutes with evidence of change in cervical dilatation or 
cervical effacement, and duration of all delivery stages. We 
also reviewed neonatal outcomes such as birth weight, birth 
length and 1-minute Apgar score. Finally, we analysed po-
tential delivery complications like a necessity of emergency 
Caesarean section, placenta abruption, placenta arrest and 
a necessity of uterine curettage after vaginal birth, as well 
as episiotomy and anaemia requiring blood transfusion. 
Statistical analysis
The study group consisted of women who received 
misoprostol, dinoprostone, and both (after dinoprostone 
was ineffective the misoprostol was used in some women). 
Thus, there were three groups of mothers. The first part of 
the analysis, which is intended to compare successful labour 
inductions after the implementation of one drug only, pre-
sents differences between ‘misoprostol only’ and ‘dinopros-
ton only’ groups. In order to compare basic characteristics 
of the study groups for interval scale variables [age, time, 
weight, body mass index (BMI)], first normal distribution 
in groups was assessed by Shapiro-Wilk test, and then for 
normally distributed variables the t-test for equal or unequal 
variances, and for skewed variables the U-Mann-Whitney 
test were used to assess significance. Chi-squared Person’s 
test was used for nominal or ordinal scale variables provided 
that the expected value of at least five was observed in 
each cell, otherwise the exact Fisher’s test was performed. 
As a next step, to reveal whether there is a difference in the 
effectiveness between implemented drugs an intention to 
treat (ITT) approach was implemented — meaning mothers 
started with misoprostol were considered as the first group, 
and mothers started with dinoproston as the second group 
irrespective of whether the mother was given later the other 
drug for induction purposes or not. The proportional Cox 
regression model was performed to assess the strength of 
difference between misoprostol and dinoprostone in the 
effectiveness of delivery upon time. The calculated hazard 
ratio shows how many times the delivery is more or less 
likely in a specified amount of time. Models were created 
as both unadjusted and adjusted for the clinically impor-
tant covariates. In addition, it was tested a possible impact 
of woman’s age on the efficacy of the treatment. For that 
purpose, firstly, a linear regression of the mother’s age on 
the time between drug implementation and the beginning 
of labour or the delivery of a baby, and additionally the 
second stage of labour, with the treatment type covariate 
were performed. Secondly, to check whether the differ-
ence between misoprostol and dinoprostone depended 
on mother’s age (the test for a modification effect of the 
mother’s age < 35, and 35+) the interaction terms between 
categorised mother’s age and a group type variable in the 
ANOVA models were used. All the analyses were done using 
the IBM SPSS Statistics version 25. Pairwise procedure was 
used for missing data. Results (differences) were considered 
statistically significant if the p-value was less than 0.05.
RESULTS
There were 560 pregnant women identified in medical 
records as admitted to the Obstetric and Perinatology De-
partment at the University Hospital in Cracow, Poland for in-
duction of delivery in the period from January 2015 till April 
2019. Out of 560, 320 were excluded due to the presence 
of any of the co-morbidity mentioned under the exclusion 
criteria. In the remaining 240 women there were 93 women 
who received misoprostol and 147 who were given dino-
prostone. In the last-mentioned group, however, there were 
39 (26.5%) which were observed as not-reacting to the drug, 
and they received after some time misoprostol additionally. 
Thus “one drug successful labour induction” groups included 
201 pregnant women, out of whom 93 (46.3%) were treated 
with misoprostol and 108 (53.7%) were given dinoprostone. 
The basic characteristics of mothers were similar across 
study groups regarding their age, gravidity, parity, weight, 
and BMI at admission. There were no statistically significant 
differences in pre-ripening cervical characteristics either, or 
the initial Bishop score in all patients was ≤ 4 (Tab. 1). Consid-
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ering gestational age, it was slightly lower in the misoprostol 
group as compared to dinoprostone group (medians: 40.6 vs 
40.9 weeks respectively, p < 0.001), additionally, estimated 
birth weight was also lower in the misoprostol group (medi-
ans: 3450 vs 3682 g, respectively, p = 0.027). The indications 
for labour induction did not differ significantly between 
the two groups, although Rh incompatibility was observed 
slightly more frequently in the dinoprostone group (4.1% 
vs 1.1%) and foetal indications (including foetal growth 
restriction) were noticed more frequently in the misoprostol 
group (16.1% vs 8.2%). Most inductions were initiated due 
to prolonged pregnancy exceeding the term date. There 
was no operative vaginal delivery. 
The proportion of mothers who underwent vaginal de-
livery was comparable between the groups, as it was 68.8% 
in the misoprostol and 76.9% in the dinoprostone group 
(p = 0.207). There were also no differences between the 
rate of Caesarean section or indications for such delivery 
between the two groups. The most often causes of Caesar-
ean section were foetal distress seen in cardiotocography 
Table 1. Clinical characteristics of the study groups (across “after one drug successful delivery” groups)







































Number of pregnancies [n, (%)] df = 2Pchi2 = 0.713
 1 52 (55.9%) 66 (61.1%)
 2 20 (21.5%) 22 (20.4%)
 ≥ 3 21 (22.6%) 20 (18.5%)




 1 64 (68.8%) 77 (71.3%)
 2 18 (19.4%) 21 (19.4%)
 3 11 (11.8%) 10 (9.3%)
Nulliparous [n, (%)] 62 (66.7%) 76 (70.4%) df = 1Pchi2 = 0.648
Miscarriage history [n, (%)] df = 1Pchi2 = 0.305
 No 70 (75.3%) 88 (81.5%)
 Yes 23 (24.7%) 20 (18.5%)
Pre–ripening cervical characteristics [n (%)]
 Dilatation ≤ 1 cm 86 (92.5%) 99 (91.7%) df = 1Pchi2 = 0.999



















*p < 0.05 by the Shapiro-Wilk test for normal distribution; #at a time of administration of the first dose of the drug; MW — the U-Mann-Whitney test; t-e — the Student’s 
t-test for equal variances; chi2 — the chi-squared test, df — degrees of freedom; F — the exact Fisher’s test
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tracing or lack of the labour progress, although there was 
significantly more often emergency Caesarean delivery out 
of all deliveries (p = 0.028) in the misoprostol group (Tab. 2). 
For the analysis of the safety, the three groups, i.e., misopros-
tol, dinoprostone and dinoprostone followed by misoprostol 
were considered. Delivery complications were categorized 
into the following: anaemia with blood transfusion need, 
uterine hyperstimulation, uterus curettage after delivery, 
shoulder dystocia or the perineum rupture needing surgical 
suturing. There were no significant differences in postpar-
tum complications between groups (Tab. 3).
The oxytocin usage to accelerate the contraction activity 
of the uterine muscle was necessary in eight patients (8.6%) 
from the misoprostol group, and in 55 patients (37.4%) from 
dinoprostone group, which reached a statistically significant 
difference (p < 0.001).
The misoprostol use appeared to significantly shorten 
the time to any delivery compared to dinoprostone gel (me-
dians: 14.5 vs 35.6 h, p < 0.001), it also shortened the time 
to beginning of delivery and vaginal delivery. There were 
no significant differences found in duration of any stage of 
labour between the two groups (Tab. 4). 
There were statistically significant differences in Apgar 
scores of the baby (Tab. 5). The birth weight and length were 
statistically different, which may reflect the previously noted 
difference in gestational age at the delivery (Tab. 1 and 5).
As a next step, we checked whether woman’s age had 
been associated with the analyzed time periods. After the 
Table 3. Postpartum complications among study participants
Misoprostol [n = 93] Dinoprostone [n = 108] Dinoprostone + misoprostol [n = 39] Significance
Any complication 14 (15.1%) 12 (11.1%) 9 (23.1%) df = 2Pchi2 = 0.196
Blood transfusion 2 (2.2%) 2 (1.9%) 2 (5.1%) PF = 0.470
Uterine hyper-stimulation 2 (2.2%) 0 2 (5.1%) PF = 0.059
Curettage after delivery 8 (8.6%) 9 (8.3%) 3 (7.7%) PF = 0.999
Episiotomy 26 (28.0%) 42 (38.9%) 17 (43.6%) df = 1Pchi2 = 0.137



















chi2 — the chi-squared test; df — degrees of freedom; F — the exact Fisher’s test
Table 2. Mode of delivery and indications for caesarean section across “after one drug successful delivery” groups
Misoprostol [n = 93] Dinoprostone [n = 108] Significance
Cesarean section 29 (31.2%) 25 (23.1%) df = 1Pchi2 = 0.207
Emergency Caesarean delivery out of 
total deliveries 19 (20.4%) 10 (9.3%)
df = 1
Pchi2 = 0.028








Vaginal delivery 64 (68.8%) 83 (76.9%) df = 1Pchi2 = 0.207
Indications for Caesarean section [n = 29] [n = 25] pF = 0.207
 Foetal distress 18 (62.1%) 10 (40.0%)
 Labor arrest during first stage (First-stage 
Caesarean) 6 (20.7%) 10 (40.0%)
 Labor arrest during second stage 
(Second-stage Caesarean) 4 (13.8%) 5 (20.0%)
 Fetal hand prolapse 1 (3.4%) 0 (0.0%)
chi2 — the chi-squared test; df — degrees of freedom; F — the exact Fisher’s test
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woman’s age was regressed on the time from the drug 
implementation to the beginning of a labour (to the first 
stage of labour), to the delivery of a baby (to the end of 
second stage of labour) and additionally on the duration of 
the second stage of a labour only, no one result was statisti-
cally significant (p values: 0.114; 0.308; 0.131, respectively). 
Additionally, when the differences in the considered time 
periods between drug types were analysed with interaction 
terms between woman’s age categorical variable no result 
had been significant either (p values: 0.970; 0.757; 0.800).
Finally, Cox regression models were performed to as-
sess whether there were differences between misoprostol 
and dinoprostone upon time in the labour induction. The 
results showed that misoprostol increased more than twice 
the chance of beginning the labour or delivery of a baby 
in comparison to dinoprostone. Even after adjustment 
for the covariates which might influence the process, like 
mother’s age, number of pregnancies, cervical state, and 
oxytocin use, the probability still was significantly higher 
(Tab. 6 and 7).




[n = 147] Significance


































































*p < 0.05 by the Shapiro-Wilk test for normal distribution; MW — the U-Mann-Whitney test
Table 5. Neonatal outcomes across intention to treat misoprostol and dinoprostone groups









Apgar score ≤ 6 points at the 1st min (n, %)
Apgar score 7–8 points at the 1st min (n, %)




























Female [n, %] 44 (47.3%) 68 (46.3%) df = 1Pchi2 = 0.895
*p < 0.05 by the Shapiro-Wilk test for normal distribution; MW — the U-Mann-Whitney test; t-ue — the Student’s t-test for unequal variances
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DISCUSSION 
The use of pharmaceutical induction of labour increased 
in many European countries during the last decades, for 
example in Norway the rate increased from 12.5% in 2003 to 
20.3% in 2013. The rate of caesarean section in the induced 
patients’ group did not change, and it remained stable at 
17.1 and 17.4%, respectively [5]. It might be connected with 
introducing into the contemporary obstetrics the use of pros-
taglandins, which facilitate cervical ripening and accelerate 
uterine contractions like in the natural course of delivery.
The purpose of this study was a comparison of two prosta-
glandins used in everyday clinical practice, which are, among 
others, recommended by the Polish Society of Gynaecologists 
and Obstetricians Guidelines for labour induction [6]. We veri-
fied that vaginally implemented misoprostol insert was more 
effective than the dinoprostone gel in induction of labour in 
pregnant women without any comorbidities at term. Our 
findings are in line with the results of Sharp et al. [7] who dem-
onstrated a statistically shorter time to the delivery when using 
misoprostol vaginal insert rather than dinoprostone vaginal 
gel, namely means 18.2 h (11.6–27.6) vs 21.8 h (19.0–23.9), 
respectively. In our study, the mean interval between the 
implementation of misoprostol to the time of delivery was 
even shorter (14.5 h). We have shown that misoprostol, in 
comparison to dinoprostone, resulted in twice higher chance 
of successful beginning of delivery regardless the number of 
previous pregnancies, gestational age or cervical state. Even 
if additionally, oxytocin use or mother’s age were considered, 
the chance of labour initiation across time was still 1.9 times 
higher in this group (Tab. 6, Fig. 1). We observed similar effects 
on the time to baby’s delivery (Tab. 7, Fig. 2). Those results indi-
cated that misoprostol was more effective than dinoprostone 
in the induction of labour, which also further supported the 
findings of the other studies [8–9,12]. It is worth mentioning 
that most of available studies are based on different routes 
of administration of misoprostol (oral tablets, tablets imple-
mented into the posterior vaginal fornix, vaginal insert) or di-
noproston (vaginal insert, vaginal gel), which may interrupt the 
direct comparison between result and conclusions of those 
studies. One study which compared misoprostol vaginal insert 
(MVI) and misoprostol vaginal tablets (MVT) for induction of 
labour in term pregnancies [10] showed that MVI achieved 
a more vaginal delivery rate within 24-hours and shorter time 
from induction to vaginal delivery than MVT, with no influence 
on caesarean section rate, postpartum haemorrhage, Apgar 
score below 7. Remarkably similar conclusions were made 
after comparing of the misoprostol vaginal insert with oral 
misoprostol tablets in favour of vaginal rout [11]. 
Table 7. The relative probability (assessed by the hazard ratio) for 
baby’s delivery for misoprostol as compared to dinoprostone
Hazard ratio 95% CI p value
Baby’s delivery 3.21 2.40–4.29 p < 0.001
Baby’s delivery1 3.07 2.28–4.13 p < 0.001
Baby’s delivery2 3.09 2.29–4.16 p < 0.001
Baby’s delivery3 2.59 1.90–3.53 p < 0.001
The proportional Cox regression model; 1Adjusted for number of pregnancies, 
mother’s age; 2Adjusted for the covariates as in (1) and additionally for 
cervical effacement; 3Adjusted for the covariates as in (2) and additionally for 
oxytocin use; CI — confidence interval
Table 6. The relative probability (assessed by the hazard ratio) for 
induction of a labor for misoprostol compared to dinoprostone
Hazard ratio 95% CI p value
Beginning of labor 2.57 1.85–3.57 p < 0.001
Beginning of labor1 2.44 1.75–3.40 p < 0.001
Beginning of labor2 2.42 1.73–3.39 p < 0.001
Beginning of labor3 2.10 1.49–2.97 p < 0.001
The proportional Cox regression model; 1Adjusted for number of pregnancies, 
mother’s age; 2Adjusted for the covariates as in (1) and additionally for 
cervical effacement; 3Adjusted for the covariates as in (2) and additionally for 
oxytocin use; CI — confidence interval
Figure 1. Cox regression model — from drug implementation to the 
beginning of labor
Figure 2. Cox regression model — from drug implementation to 
baby’s delivery
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The results of our study suggested that use of misopros-
tol vaginal insert shorten the time intervals from medica-
ment implementation to active labour and to delivery itself 
when compared with preinduction with dinoprostone. 
Incidence of vaginal deliveries after induction of labour 
vary widely in the literature; it was 92.5% [7], 88% [12], 73.3% 
[8] in the misoprostol group, compared with dinoprostone 
89,1%, 74%, 71,6% respectively. In our study, the misoprostol 
intervention ended in the vaginal delivery in 68.8% cases in 
comparison to 76.9% in the dinoprostone group. 
We observed lower mean birth weight of the neonates 
in the misoprostol group, which we assumed that was most-
ly connected with the lower gestational age in this group 
(40.6 vs 40.9 p < 0.001). However, we believe that it had no 
influence on the effectiveness of misoprostol, since there 
was another study where the misoprostol group had higher 
mean birth weight and gestational age compared to the 
dinoprostone group and the time interval to delivery was still 
shorter [12] or in another one in which the time from drug ap-
plication to onset of labour was also significantly reduced [13].
As the prostaglandins’ administration may result in many 
adverse outcomes, in both the mother and the infant, we 
analysed the results thoroughly. In both groups we have no-
ticed disturbances in the foetal heart rate pattern described 
as foetal distress needing emergency caesarean delivery, 
with no statistical difference. In the end of our observation, 
we have shown that the caesarean delivery rates and its 
indications, as well as the maternal complications were not 
significantly different between studied groups. 
In our study the analysis of the factors that potential-
ly might have influenced the effect of each intervention 
showed no differences between the groups regarding ma-
ternal age, parity, prior vaginal delivery, miscarriage history, 
patients’ body mass index, Bishop’s scale score before the 
drug administration or estimated foetal weight. 
There were a few limitations of this work that should be 
acknowledged. First, the study was retrospective and the 
enrolment of subjects for this study was not randomised. 
Additionally, we reviewed medical records as the source 
of information, and there were several missing data which 
were not possible to retrieve. Moreover, our sample size 
was limited; however, it was big enough to reach statistical 
significance for some of our results. It was not observed in 
our study any significant difference in the complication rate 
between different drugs, but, in our opinion, it should be 
confirmed on large sample size study. Thus, further studies 
on bigger groups are still needed.
CONCLUSIONS
Our study showed that using the misoprostol vaginal 
insert in comparison to dinoprostone gel seems to increase 
the chance of delivery and to shorten the time to beginning 
of the first stage of labour as well as the time to the delivery 
itself regardless the way, vaginal birth or caesarean section 
with no influence on maternal complications. Some lower 
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